The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review
Abstract A move is under way towards personalised cancer treatment, where tumour biology of an individual patient is examined to give unique predictive and prognostic information. This is extremely important in the setting of older women, who have treatment-specific goals which may differ from their...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Gordon-Craig, Sophie [verfasserIn] Parks, Ruth M. [verfasserIn] Cheung, Kwok-Leung [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Rare Cancers and Therapy - [Tarpoley] : Springer Healthcare, 2013, 8(2020), 2 vom: 17. Juli, Seite 231-250 |
|---|---|
| Übergeordnetes Werk: |
volume:8 ; year:2020 ; number:2 ; day:17 ; month:07 ; pages:231-250 |
| Links: |
|---|
| DOI / URN: |
10.1007/s40487-020-00123-3 |
|---|
| Katalog-ID: |
SPR042118573 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR042118573 | ||
| 003 | DE-627 | ||
| 005 | 20230519091845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201126s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40487-020-00123-3 |2 doi | |
| 035 | |a (DE-627)SPR042118573 | ||
| 035 | |a (SPR)s40487-020-00123-3-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Gordon-Craig, Sophie |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract A move is under way towards personalised cancer treatment, where tumour biology of an individual patient is examined to give unique predictive and prognostic information. This is extremely important in the setting of older women, who have treatment-specific goals which may differ from their younger counterparts, and may include conservation of quality of life rather than curative intent of treatment. One method employed to assist with this is the use of tumour-based prognostic and predictive tools. This article explores six of the most common tumour-based tools currently available on the market: MammaPrint, Oncotype DX, Mammostrat, Prosigna, EndoPredict, IHC4. The article discusses the creation and validation of these tools, their use and validation in older women, and future directions in the field. With the exception of Oncotype Dx, which has also been licensed for prediction of response from adjuvant chemotherapy, these tools have been licensed for use as prognostic tools only, mainly in the setting of adjuvant therapy following surgery. The evidence base for use in older women is strongest for Mammostrat and PAM50, although overall the evidence is much weaker than that in younger women. Where older women have been included in validation studies, this is often in small numbers, or the exact proportion of older women is unknown. In practice, all six of the tools are recommended to be utilised on surgical excision specimens, as well as in core needle biopsy (CNB) specimens in all of the tools except Mammostrat. This is extremely important in the setting of older women, of whom a large proportion do not undergo surgery. The suggested nature of the sample is formalin-fixed paraffin-embedded in all the tools except MammaPrint, which can also be performed on fresh-frozen samples. Future development of prognostic tools in older women with breast cancer should focus on treatment dilemmas specific to this population. This includes the decision of primary treatment between surgery or endocrine therapy and decisions regarding adjuvant therapy, in particular, chemotherapy. | ||
| 650 | 4 | |a Breast cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Older women |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Prediction tools |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Prognostic tools |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Parks, Ruth M. |e verfasserin |4 aut | |
| 700 | 1 | |a Cheung, Kwok-Leung |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rare Cancers and Therapy |d [Tarpoley] : Springer Healthcare, 2013 |g 8(2020), 2 vom: 17. Juli, Seite 231-250 |w (DE-627)815914717 |w (DE-600)2806675-3 |x 2195-6022 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2020 |g number:2 |g day:17 |g month:07 |g pages:231-250 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40487-020-00123-3 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2020 |e 2 |b 17 |c 07 |h 231-250 | ||
| author_variant |
s g c sgc r m p rm rmp k l c klc |
|---|---|
| matchkey_str |
article:21956022:2020----::hptnilsotmubsdrgotcnpeitvtosnlewmnihrmr |
| hierarchy_sort_str |
2020 |
| publishDate |
2020 |
| allfields |
10.1007/s40487-020-00123-3 doi (DE-627)SPR042118573 (SPR)s40487-020-00123-3-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE Gordon-Craig, Sophie verfasserin aut The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract A move is under way towards personalised cancer treatment, where tumour biology of an individual patient is examined to give unique predictive and prognostic information. This is extremely important in the setting of older women, who have treatment-specific goals which may differ from their younger counterparts, and may include conservation of quality of life rather than curative intent of treatment. One method employed to assist with this is the use of tumour-based prognostic and predictive tools. This article explores six of the most common tumour-based tools currently available on the market: MammaPrint, Oncotype DX, Mammostrat, Prosigna, EndoPredict, IHC4. The article discusses the creation and validation of these tools, their use and validation in older women, and future directions in the field. With the exception of Oncotype Dx, which has also been licensed for prediction of response from adjuvant chemotherapy, these tools have been licensed for use as prognostic tools only, mainly in the setting of adjuvant therapy following surgery. The evidence base for use in older women is strongest for Mammostrat and PAM50, although overall the evidence is much weaker than that in younger women. Where older women have been included in validation studies, this is often in small numbers, or the exact proportion of older women is unknown. In practice, all six of the tools are recommended to be utilised on surgical excision specimens, as well as in core needle biopsy (CNB) specimens in all of the tools except Mammostrat. This is extremely important in the setting of older women, of whom a large proportion do not undergo surgery. The suggested nature of the sample is formalin-fixed paraffin-embedded in all the tools except MammaPrint, which can also be performed on fresh-frozen samples. Future development of prognostic tools in older women with breast cancer should focus on treatment dilemmas specific to this population. This includes the decision of primary treatment between surgery or endocrine therapy and decisions regarding adjuvant therapy, in particular, chemotherapy. Breast cancer (dpeaa)DE-He213 Older women (dpeaa)DE-He213 Prediction tools (dpeaa)DE-He213 Prognostic tools (dpeaa)DE-He213 Parks, Ruth M. verfasserin aut Cheung, Kwok-Leung verfasserin aut Enthalten in Rare Cancers and Therapy [Tarpoley] : Springer Healthcare, 2013 8(2020), 2 vom: 17. Juli, Seite 231-250 (DE-627)815914717 (DE-600)2806675-3 2195-6022 nnns volume:8 year:2020 number:2 day:17 month:07 pages:231-250 https://dx.doi.org/10.1007/s40487-020-00123-3 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 8 2020 2 17 07 231-250 |
| spelling |
10.1007/s40487-020-00123-3 doi (DE-627)SPR042118573 (SPR)s40487-020-00123-3-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE Gordon-Craig, Sophie verfasserin aut The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract A move is under way towards personalised cancer treatment, where tumour biology of an individual patient is examined to give unique predictive and prognostic information. This is extremely important in the setting of older women, who have treatment-specific goals which may differ from their younger counterparts, and may include conservation of quality of life rather than curative intent of treatment. One method employed to assist with this is the use of tumour-based prognostic and predictive tools. This article explores six of the most common tumour-based tools currently available on the market: MammaPrint, Oncotype DX, Mammostrat, Prosigna, EndoPredict, IHC4. The article discusses the creation and validation of these tools, their use and validation in older women, and future directions in the field. With the exception of Oncotype Dx, which has also been licensed for prediction of response from adjuvant chemotherapy, these tools have been licensed for use as prognostic tools only, mainly in the setting of adjuvant therapy following surgery. The evidence base for use in older women is strongest for Mammostrat and PAM50, although overall the evidence is much weaker than that in younger women. Where older women have been included in validation studies, this is often in small numbers, or the exact proportion of older women is unknown. In practice, all six of the tools are recommended to be utilised on surgical excision specimens, as well as in core needle biopsy (CNB) specimens in all of the tools except Mammostrat. This is extremely important in the setting of older women, of whom a large proportion do not undergo surgery. The suggested nature of the sample is formalin-fixed paraffin-embedded in all the tools except MammaPrint, which can also be performed on fresh-frozen samples. Future development of prognostic tools in older women with breast cancer should focus on treatment dilemmas specific to this population. This includes the decision of primary treatment between surgery or endocrine therapy and decisions regarding adjuvant therapy, in particular, chemotherapy. Breast cancer (dpeaa)DE-He213 Older women (dpeaa)DE-He213 Prediction tools (dpeaa)DE-He213 Prognostic tools (dpeaa)DE-He213 Parks, Ruth M. verfasserin aut Cheung, Kwok-Leung verfasserin aut Enthalten in Rare Cancers and Therapy [Tarpoley] : Springer Healthcare, 2013 8(2020), 2 vom: 17. Juli, Seite 231-250 (DE-627)815914717 (DE-600)2806675-3 2195-6022 nnns volume:8 year:2020 number:2 day:17 month:07 pages:231-250 https://dx.doi.org/10.1007/s40487-020-00123-3 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 8 2020 2 17 07 231-250 |
| allfields_unstemmed |
10.1007/s40487-020-00123-3 doi (DE-627)SPR042118573 (SPR)s40487-020-00123-3-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE Gordon-Craig, Sophie verfasserin aut The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract A move is under way towards personalised cancer treatment, where tumour biology of an individual patient is examined to give unique predictive and prognostic information. This is extremely important in the setting of older women, who have treatment-specific goals which may differ from their younger counterparts, and may include conservation of quality of life rather than curative intent of treatment. One method employed to assist with this is the use of tumour-based prognostic and predictive tools. This article explores six of the most common tumour-based tools currently available on the market: MammaPrint, Oncotype DX, Mammostrat, Prosigna, EndoPredict, IHC4. The article discusses the creation and validation of these tools, their use and validation in older women, and future directions in the field. With the exception of Oncotype Dx, which has also been licensed for prediction of response from adjuvant chemotherapy, these tools have been licensed for use as prognostic tools only, mainly in the setting of adjuvant therapy following surgery. The evidence base for use in older women is strongest for Mammostrat and PAM50, although overall the evidence is much weaker than that in younger women. Where older women have been included in validation studies, this is often in small numbers, or the exact proportion of older women is unknown. In practice, all six of the tools are recommended to be utilised on surgical excision specimens, as well as in core needle biopsy (CNB) specimens in all of the tools except Mammostrat. This is extremely important in the setting of older women, of whom a large proportion do not undergo surgery. The suggested nature of the sample is formalin-fixed paraffin-embedded in all the tools except MammaPrint, which can also be performed on fresh-frozen samples. Future development of prognostic tools in older women with breast cancer should focus on treatment dilemmas specific to this population. This includes the decision of primary treatment between surgery or endocrine therapy and decisions regarding adjuvant therapy, in particular, chemotherapy. Breast cancer (dpeaa)DE-He213 Older women (dpeaa)DE-He213 Prediction tools (dpeaa)DE-He213 Prognostic tools (dpeaa)DE-He213 Parks, Ruth M. verfasserin aut Cheung, Kwok-Leung verfasserin aut Enthalten in Rare Cancers and Therapy [Tarpoley] : Springer Healthcare, 2013 8(2020), 2 vom: 17. Juli, Seite 231-250 (DE-627)815914717 (DE-600)2806675-3 2195-6022 nnns volume:8 year:2020 number:2 day:17 month:07 pages:231-250 https://dx.doi.org/10.1007/s40487-020-00123-3 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 8 2020 2 17 07 231-250 |
| allfieldsGer |
10.1007/s40487-020-00123-3 doi (DE-627)SPR042118573 (SPR)s40487-020-00123-3-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE Gordon-Craig, Sophie verfasserin aut The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract A move is under way towards personalised cancer treatment, where tumour biology of an individual patient is examined to give unique predictive and prognostic information. This is extremely important in the setting of older women, who have treatment-specific goals which may differ from their younger counterparts, and may include conservation of quality of life rather than curative intent of treatment. One method employed to assist with this is the use of tumour-based prognostic and predictive tools. This article explores six of the most common tumour-based tools currently available on the market: MammaPrint, Oncotype DX, Mammostrat, Prosigna, EndoPredict, IHC4. The article discusses the creation and validation of these tools, their use and validation in older women, and future directions in the field. With the exception of Oncotype Dx, which has also been licensed for prediction of response from adjuvant chemotherapy, these tools have been licensed for use as prognostic tools only, mainly in the setting of adjuvant therapy following surgery. The evidence base for use in older women is strongest for Mammostrat and PAM50, although overall the evidence is much weaker than that in younger women. Where older women have been included in validation studies, this is often in small numbers, or the exact proportion of older women is unknown. In practice, all six of the tools are recommended to be utilised on surgical excision specimens, as well as in core needle biopsy (CNB) specimens in all of the tools except Mammostrat. This is extremely important in the setting of older women, of whom a large proportion do not undergo surgery. The suggested nature of the sample is formalin-fixed paraffin-embedded in all the tools except MammaPrint, which can also be performed on fresh-frozen samples. Future development of prognostic tools in older women with breast cancer should focus on treatment dilemmas specific to this population. This includes the decision of primary treatment between surgery or endocrine therapy and decisions regarding adjuvant therapy, in particular, chemotherapy. Breast cancer (dpeaa)DE-He213 Older women (dpeaa)DE-He213 Prediction tools (dpeaa)DE-He213 Prognostic tools (dpeaa)DE-He213 Parks, Ruth M. verfasserin aut Cheung, Kwok-Leung verfasserin aut Enthalten in Rare Cancers and Therapy [Tarpoley] : Springer Healthcare, 2013 8(2020), 2 vom: 17. Juli, Seite 231-250 (DE-627)815914717 (DE-600)2806675-3 2195-6022 nnns volume:8 year:2020 number:2 day:17 month:07 pages:231-250 https://dx.doi.org/10.1007/s40487-020-00123-3 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 8 2020 2 17 07 231-250 |
| allfieldsSound |
10.1007/s40487-020-00123-3 doi (DE-627)SPR042118573 (SPR)s40487-020-00123-3-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE Gordon-Craig, Sophie verfasserin aut The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract A move is under way towards personalised cancer treatment, where tumour biology of an individual patient is examined to give unique predictive and prognostic information. This is extremely important in the setting of older women, who have treatment-specific goals which may differ from their younger counterparts, and may include conservation of quality of life rather than curative intent of treatment. One method employed to assist with this is the use of tumour-based prognostic and predictive tools. This article explores six of the most common tumour-based tools currently available on the market: MammaPrint, Oncotype DX, Mammostrat, Prosigna, EndoPredict, IHC4. The article discusses the creation and validation of these tools, their use and validation in older women, and future directions in the field. With the exception of Oncotype Dx, which has also been licensed for prediction of response from adjuvant chemotherapy, these tools have been licensed for use as prognostic tools only, mainly in the setting of adjuvant therapy following surgery. The evidence base for use in older women is strongest for Mammostrat and PAM50, although overall the evidence is much weaker than that in younger women. Where older women have been included in validation studies, this is often in small numbers, or the exact proportion of older women is unknown. In practice, all six of the tools are recommended to be utilised on surgical excision specimens, as well as in core needle biopsy (CNB) specimens in all of the tools except Mammostrat. This is extremely important in the setting of older women, of whom a large proportion do not undergo surgery. The suggested nature of the sample is formalin-fixed paraffin-embedded in all the tools except MammaPrint, which can also be performed on fresh-frozen samples. Future development of prognostic tools in older women with breast cancer should focus on treatment dilemmas specific to this population. This includes the decision of primary treatment between surgery or endocrine therapy and decisions regarding adjuvant therapy, in particular, chemotherapy. Breast cancer (dpeaa)DE-He213 Older women (dpeaa)DE-He213 Prediction tools (dpeaa)DE-He213 Prognostic tools (dpeaa)DE-He213 Parks, Ruth M. verfasserin aut Cheung, Kwok-Leung verfasserin aut Enthalten in Rare Cancers and Therapy [Tarpoley] : Springer Healthcare, 2013 8(2020), 2 vom: 17. Juli, Seite 231-250 (DE-627)815914717 (DE-600)2806675-3 2195-6022 nnns volume:8 year:2020 number:2 day:17 month:07 pages:231-250 https://dx.doi.org/10.1007/s40487-020-00123-3 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 8 2020 2 17 07 231-250 |
| language |
English |
| source |
Enthalten in Rare Cancers and Therapy 8(2020), 2 vom: 17. Juli, Seite 231-250 volume:8 year:2020 number:2 day:17 month:07 pages:231-250 |
| sourceStr |
Enthalten in Rare Cancers and Therapy 8(2020), 2 vom: 17. Juli, Seite 231-250 volume:8 year:2020 number:2 day:17 month:07 pages:231-250 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Breast cancer Older women Prediction tools Prognostic tools |
| dewey-raw |
610 |
| isfreeaccess_bool |
true |
| container_title |
Rare Cancers and Therapy |
| authorswithroles_txt_mv |
Gordon-Craig, Sophie @@aut@@ Parks, Ruth M. @@aut@@ Cheung, Kwok-Leung @@aut@@ |
| publishDateDaySort_date |
2020-07-17T00:00:00Z |
| hierarchy_top_id |
815914717 |
| dewey-sort |
3610 |
| id |
SPR042118573 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR042118573</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519091845.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201126s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s40487-020-00123-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR042118573</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s40487-020-00123-3-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Gordon-Craig, Sophie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract A move is under way towards personalised cancer treatment, where tumour biology of an individual patient is examined to give unique predictive and prognostic information. This is extremely important in the setting of older women, who have treatment-specific goals which may differ from their younger counterparts, and may include conservation of quality of life rather than curative intent of treatment. One method employed to assist with this is the use of tumour-based prognostic and predictive tools. This article explores six of the most common tumour-based tools currently available on the market: MammaPrint, Oncotype DX, Mammostrat, Prosigna, EndoPredict, IHC4. The article discusses the creation and validation of these tools, their use and validation in older women, and future directions in the field. With the exception of Oncotype Dx, which has also been licensed for prediction of response from adjuvant chemotherapy, these tools have been licensed for use as prognostic tools only, mainly in the setting of adjuvant therapy following surgery. The evidence base for use in older women is strongest for Mammostrat and PAM50, although overall the evidence is much weaker than that in younger women. Where older women have been included in validation studies, this is often in small numbers, or the exact proportion of older women is unknown. In practice, all six of the tools are recommended to be utilised on surgical excision specimens, as well as in core needle biopsy (CNB) specimens in all of the tools except Mammostrat. This is extremely important in the setting of older women, of whom a large proportion do not undergo surgery. The suggested nature of the sample is formalin-fixed paraffin-embedded in all the tools except MammaPrint, which can also be performed on fresh-frozen samples. Future development of prognostic tools in older women with breast cancer should focus on treatment dilemmas specific to this population. This includes the decision of primary treatment between surgery or endocrine therapy and decisions regarding adjuvant therapy, in particular, chemotherapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Breast cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Older women</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prediction tools</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prognostic tools</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Parks, Ruth M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cheung, Kwok-Leung</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Rare Cancers and Therapy</subfield><subfield code="d">[Tarpoley] : Springer Healthcare, 2013</subfield><subfield code="g">8(2020), 2 vom: 17. Juli, Seite 231-250</subfield><subfield code="w">(DE-627)815914717</subfield><subfield code="w">(DE-600)2806675-3</subfield><subfield code="x">2195-6022</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:2</subfield><subfield code="g">day:17</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:231-250</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s40487-020-00123-3</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2020</subfield><subfield code="e">2</subfield><subfield code="b">17</subfield><subfield code="c">07</subfield><subfield code="h">231-250</subfield></datafield></record></collection>
|
| author |
Gordon-Craig, Sophie |
| spellingShingle |
Gordon-Craig, Sophie ddc 610 misc Breast cancer misc Older women misc Prediction tools misc Prognostic tools The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review |
| authorStr |
Gordon-Craig, Sophie |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)815914717 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
2195-6022 |
| topic_title |
610 ASE The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review Breast cancer (dpeaa)DE-He213 Older women (dpeaa)DE-He213 Prediction tools (dpeaa)DE-He213 Prognostic tools (dpeaa)DE-He213 |
| topic |
ddc 610 misc Breast cancer misc Older women misc Prediction tools misc Prognostic tools |
| topic_unstemmed |
ddc 610 misc Breast cancer misc Older women misc Prediction tools misc Prognostic tools |
| topic_browse |
ddc 610 misc Breast cancer misc Older women misc Prediction tools misc Prognostic tools |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Rare Cancers and Therapy |
| hierarchy_parent_id |
815914717 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Rare Cancers and Therapy |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)815914717 (DE-600)2806675-3 |
| title |
The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review |
| ctrlnum |
(DE-627)SPR042118573 (SPR)s40487-020-00123-3-e |
| title_full |
The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review |
| author_sort |
Gordon-Craig, Sophie |
| journal |
Rare Cancers and Therapy |
| journalStr |
Rare Cancers and Therapy |
| lang_code |
eng |
| isOA_bool |
true |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
txt |
| container_start_page |
231 |
| author_browse |
Gordon-Craig, Sophie Parks, Ruth M. Cheung, Kwok-Leung |
| container_volume |
8 |
| class |
610 ASE |
| format_se |
Elektronische Aufsätze |
| author-letter |
Gordon-Craig, Sophie |
| doi_str_mv |
10.1007/s40487-020-00123-3 |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
potential use of tumour-based prognostic and predictive tools in older women with primary breast cancer: a narrative review |
| title_auth |
The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review |
| abstract |
Abstract A move is under way towards personalised cancer treatment, where tumour biology of an individual patient is examined to give unique predictive and prognostic information. This is extremely important in the setting of older women, who have treatment-specific goals which may differ from their younger counterparts, and may include conservation of quality of life rather than curative intent of treatment. One method employed to assist with this is the use of tumour-based prognostic and predictive tools. This article explores six of the most common tumour-based tools currently available on the market: MammaPrint, Oncotype DX, Mammostrat, Prosigna, EndoPredict, IHC4. The article discusses the creation and validation of these tools, their use and validation in older women, and future directions in the field. With the exception of Oncotype Dx, which has also been licensed for prediction of response from adjuvant chemotherapy, these tools have been licensed for use as prognostic tools only, mainly in the setting of adjuvant therapy following surgery. The evidence base for use in older women is strongest for Mammostrat and PAM50, although overall the evidence is much weaker than that in younger women. Where older women have been included in validation studies, this is often in small numbers, or the exact proportion of older women is unknown. In practice, all six of the tools are recommended to be utilised on surgical excision specimens, as well as in core needle biopsy (CNB) specimens in all of the tools except Mammostrat. This is extremely important in the setting of older women, of whom a large proportion do not undergo surgery. The suggested nature of the sample is formalin-fixed paraffin-embedded in all the tools except MammaPrint, which can also be performed on fresh-frozen samples. Future development of prognostic tools in older women with breast cancer should focus on treatment dilemmas specific to this population. This includes the decision of primary treatment between surgery or endocrine therapy and decisions regarding adjuvant therapy, in particular, chemotherapy. |
| abstractGer |
Abstract A move is under way towards personalised cancer treatment, where tumour biology of an individual patient is examined to give unique predictive and prognostic information. This is extremely important in the setting of older women, who have treatment-specific goals which may differ from their younger counterparts, and may include conservation of quality of life rather than curative intent of treatment. One method employed to assist with this is the use of tumour-based prognostic and predictive tools. This article explores six of the most common tumour-based tools currently available on the market: MammaPrint, Oncotype DX, Mammostrat, Prosigna, EndoPredict, IHC4. The article discusses the creation and validation of these tools, their use and validation in older women, and future directions in the field. With the exception of Oncotype Dx, which has also been licensed for prediction of response from adjuvant chemotherapy, these tools have been licensed for use as prognostic tools only, mainly in the setting of adjuvant therapy following surgery. The evidence base for use in older women is strongest for Mammostrat and PAM50, although overall the evidence is much weaker than that in younger women. Where older women have been included in validation studies, this is often in small numbers, or the exact proportion of older women is unknown. In practice, all six of the tools are recommended to be utilised on surgical excision specimens, as well as in core needle biopsy (CNB) specimens in all of the tools except Mammostrat. This is extremely important in the setting of older women, of whom a large proportion do not undergo surgery. The suggested nature of the sample is formalin-fixed paraffin-embedded in all the tools except MammaPrint, which can also be performed on fresh-frozen samples. Future development of prognostic tools in older women with breast cancer should focus on treatment dilemmas specific to this population. This includes the decision of primary treatment between surgery or endocrine therapy and decisions regarding adjuvant therapy, in particular, chemotherapy. |
| abstract_unstemmed |
Abstract A move is under way towards personalised cancer treatment, where tumour biology of an individual patient is examined to give unique predictive and prognostic information. This is extremely important in the setting of older women, who have treatment-specific goals which may differ from their younger counterparts, and may include conservation of quality of life rather than curative intent of treatment. One method employed to assist with this is the use of tumour-based prognostic and predictive tools. This article explores six of the most common tumour-based tools currently available on the market: MammaPrint, Oncotype DX, Mammostrat, Prosigna, EndoPredict, IHC4. The article discusses the creation and validation of these tools, their use and validation in older women, and future directions in the field. With the exception of Oncotype Dx, which has also been licensed for prediction of response from adjuvant chemotherapy, these tools have been licensed for use as prognostic tools only, mainly in the setting of adjuvant therapy following surgery. The evidence base for use in older women is strongest for Mammostrat and PAM50, although overall the evidence is much weaker than that in younger women. Where older women have been included in validation studies, this is often in small numbers, or the exact proportion of older women is unknown. In practice, all six of the tools are recommended to be utilised on surgical excision specimens, as well as in core needle biopsy (CNB) specimens in all of the tools except Mammostrat. This is extremely important in the setting of older women, of whom a large proportion do not undergo surgery. The suggested nature of the sample is formalin-fixed paraffin-embedded in all the tools except MammaPrint, which can also be performed on fresh-frozen samples. Future development of prognostic tools in older women with breast cancer should focus on treatment dilemmas specific to this population. This includes the decision of primary treatment between surgery or endocrine therapy and decisions regarding adjuvant therapy, in particular, chemotherapy. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA |
| container_issue |
2 |
| title_short |
The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review |
| url |
https://dx.doi.org/10.1007/s40487-020-00123-3 |
| remote_bool |
true |
| author2 |
Parks, Ruth M. Cheung, Kwok-Leung |
| author2Str |
Parks, Ruth M. Cheung, Kwok-Leung |
| ppnlink |
815914717 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s40487-020-00123-3 |
| up_date |
2024-07-04T00:53:50.094Z |
| _version_ |
1803607794091294720 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR042118573</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519091845.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201126s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s40487-020-00123-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR042118573</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s40487-020-00123-3-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Gordon-Craig, Sophie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract A move is under way towards personalised cancer treatment, where tumour biology of an individual patient is examined to give unique predictive and prognostic information. This is extremely important in the setting of older women, who have treatment-specific goals which may differ from their younger counterparts, and may include conservation of quality of life rather than curative intent of treatment. One method employed to assist with this is the use of tumour-based prognostic and predictive tools. This article explores six of the most common tumour-based tools currently available on the market: MammaPrint, Oncotype DX, Mammostrat, Prosigna, EndoPredict, IHC4. The article discusses the creation and validation of these tools, their use and validation in older women, and future directions in the field. With the exception of Oncotype Dx, which has also been licensed for prediction of response from adjuvant chemotherapy, these tools have been licensed for use as prognostic tools only, mainly in the setting of adjuvant therapy following surgery. The evidence base for use in older women is strongest for Mammostrat and PAM50, although overall the evidence is much weaker than that in younger women. Where older women have been included in validation studies, this is often in small numbers, or the exact proportion of older women is unknown. In practice, all six of the tools are recommended to be utilised on surgical excision specimens, as well as in core needle biopsy (CNB) specimens in all of the tools except Mammostrat. This is extremely important in the setting of older women, of whom a large proportion do not undergo surgery. The suggested nature of the sample is formalin-fixed paraffin-embedded in all the tools except MammaPrint, which can also be performed on fresh-frozen samples. Future development of prognostic tools in older women with breast cancer should focus on treatment dilemmas specific to this population. This includes the decision of primary treatment between surgery or endocrine therapy and decisions regarding adjuvant therapy, in particular, chemotherapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Breast cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Older women</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prediction tools</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prognostic tools</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Parks, Ruth M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cheung, Kwok-Leung</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Rare Cancers and Therapy</subfield><subfield code="d">[Tarpoley] : Springer Healthcare, 2013</subfield><subfield code="g">8(2020), 2 vom: 17. Juli, Seite 231-250</subfield><subfield code="w">(DE-627)815914717</subfield><subfield code="w">(DE-600)2806675-3</subfield><subfield code="x">2195-6022</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:2</subfield><subfield code="g">day:17</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:231-250</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s40487-020-00123-3</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2020</subfield><subfield code="e">2</subfield><subfield code="b">17</subfield><subfield code="c">07</subfield><subfield code="h">231-250</subfield></datafield></record></collection>
|
| score |
7.398178 |